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Abstract
Background: Cryopyrin-associated periodic syndrome (CAPS) is a rare autoinflammatory disease, caused by gain of
function mutation in NLRP3 resulting in excess production of interleukin-1 (IL-1). Canakinumab is a human
monoclonal antibody against Interleukin-1 beta (IL-1β), licensed for the treatment of CAPS. The objective of
the study was to describe the feasibility and cost-effectiveness of a canakinumab vial-sharing programme for
paediatric patients with CAPS.
Method: Retrospective case series and clinical service description of a national specially commissioned CAPS
clinic at Great Ormond Street Hospital (GOSH). Effectiveness was assessed using a CAPS disease activity score
(DAS) and serum amyloid A protein (SAA). Adverse events were collected to determine safety. The number of
canakinumab vials saved was considered when investigating the cost-effectiveness of vial-sharing.
Results: Nineteen/20 (95%) of our paediatric patients achieved minimally active clinical disease activity with
canakinumab monotherapy; and 75% achieved both minimally active clinical disease and serological remission
using a pre-specified definition based on the CAPS DAS and SAA level. Canakinumab was well tolerated, with
only one child developing an infection requiring hospitalisation during the study. Canakinumab vial sharing
resulted in 117 vials of canakinumab saved over a 24-month period, equating to a direct drug-related cost
saving of £1,385,821, and a conservative estimated 5-year cost-saving of £3,464,552.50.
Conclusion: We provide further evidence for the effectiveness and safety of canakinumab in children with CAPS, and
highlight the cost-effectiveness of a vial-sharing programme for this high cost medicine. We suggest that this could
have important implications for the delivery of other high cost medicines used in paediatric practice.
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Background
Cryopyrin-associated periodic syndromes (CAPS) are a
group of rare, monogenic, autoinflammatory diseases
caused by a gain of function mutation in NLR family
pyrin domain containing 3 (NLRP3), which results in ex-
cess production of interleukin-1 beta (IL-1β) [1]. This
triggers disabling multi-system inflammation from birth,
with systemic and organ-specific complications of vary-
ing severity, and a long-term risk of reactive, AA amyl-
oidosis. Three main phenotypes are recognised on a
continuum of severity [1–3]. The most severe form of
CAPS is Chronic Infantile Neurological Cutaneous Ar-
ticular syndrome (CINCA), associated with severe sys-
temic inflammation from early in life with urticarial
rash, central nervous system inflammation, neurological
impairment, various inflammatory ophthalmological se-
quelae, severe musculoskeletal morbidity, and impair-
ment of growth and development. Muckle-Wells
syndrome (MWS) is of intermediate severity, with skin
rash, periodic fever, and risk of sensorineural hearing
loss. The mildest form is familial cold-induced autoin-
flammatory syndrome (FCAS), typified by cold-induced
urticaria, myalgia, malaise and fatigue. There is a sur-
prising lack of genotype-phenotype correlation and little
reliable prediction of disease severity based on specific
NLRP3 mutations [4].
Canakinumab is a high affinity IgG1 monoclonal anti-
body against interleukin 1β which first received a licence
for the treatment of CAPS in 2009. Canakinumab is cur-
rently licensed for CAPS in patients from the age of 2
years upwards, and is highly efficacious in this context,
resulting in rapid relief of symptoms and normalisation of
acute-phase responses in most patients with CAPS [5].
We previously described the paediatric component of
a new nationally commissioned highly specialised service
for patients in England with CAPS, adding real-world
experience regarding the use of canakinumab in a paedi-
atric setting, with outcome data subsequently updated
and published online every 2 years [3] (https://www.
gosh.nhs.uk/conditions-and-treatments/clinical-outcomes/
rheumatology-clinical-outcomes). Over the first 2 years of
this clinic, it became increasingly apparent that dosing
young children using adult sized vials (150 mg per vial)
resulted in considerable drug wastage, since paediatric
doses are based on weight, typically starting at 2 mg/kg
subcutaneously every 8 weeks for children 10 kg up-
wards. To address this issue, we introduced a vial-
sharing programme for children receiving canakinumab
for CAPS at Great Ormond Street Hospital NHS
Foundation Trust (GOSH). The purpose of this study
was to describe the impact of this innovation, and de-
scribe generic lessons learned that could have impli-
cations when considering similar cost saving initiatives
for other high-cost medicines.
Materials and methods
Aims and objectives
The aim of the project was to report the clinical and
cost-effectiveness of a vial-sharing programme for cana-
kinumab treatment in paediatric patients with CAPS at
the Nationally Specialist Commissioned CAPS clinic at
Great Ormond Street Hospital (GOSH) NHS Founda-
tion Trust.
The objectives of this project were to:
1. Describe the demographics of the expanding cohort
of paediatric patients attending a national specialist
clinic for CAPS at GOSH.
2. Describe the therapeutic effectiveness of canakinumab,
using a standardised disease activity score and a
sensitive serological marker of inflammation
(Serum amyloid A).
3. Describe safety based on adverse events.
4. Assess the cost of canakinumab in this context, and
the economic impact of a systematic vial-sharing
program at GOSH, including the development of a
spreadsheet package to facilitate this analysis
retrospectively, and to model future cost savings
based on projected growth of the clinical service
over the next 5 years.
Design and patients
This was a single-centre, retrospective, observational
study of paediatric CAPS patients receiving canakinu-
mab between November 1st 2015, and October 31st
2017 at the national specially commissioned CAPS
Clinic at GOSH. This is the only specialised paediatric
service across the United Kingdom for patients with this
ultra-rare autosomal dominant genetic disease. Since this
was a retrospective case notes review with presentation
of fully anonymised data, written patient/parental con-
sent was not required. Patients with CAPS were eligible
for canakinumab treatment if they were ≥ 2 years of age;
had clinical features of active CAPS requiring medical
intervention; and had a confirmed mutation in the
NLRP3 gene; or had characteristic clinical features of
CAPS if they were NLRP3 mutation negative [6]. Exclu-
sion criteria were evidence of a pre-existing underlying
infection or any other significant medical condition that
would preclude treatment with canakinumab. Research
and ethical approval for this retrospective study was
granted from the Joint Research and Development Office
of Great Ormond Street Hospital, in accordance with
UK law (reference number 16IR47).
Assessment of CAPS disease activity
A standardised approach was used to monitor CAPS dis-
ease activity, as described previously in this clinic [3]. In
brief, this consisted of standardised documentation of
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clinical disease activity using the CAPS disease activity
score (DAS) (please see Additional file 1). The DAS de-
picts disease activity using ten symptoms/signs; absence
of disease activity was defined as a score of 0/20; min-
imal disease activity was depicted by a score ≤ 3/20; and
a maximum score of 20 indicated maximal disease activ-
ity [3]. Serological response was monitored using serum
amyloid A (SAA, reference range < 10 mg/L). Using
these indices, minimally active disease was defined as
absent or minimal disease activity (DAS ≤3/20 with no
item scoring as severe) and normal markers of in-
flammation (SAA < 10 mg/L). The CAPS DAS and
SAA (plus other routine investigations: full blood
count, renal and liver function; and C-reactive pro-
tein) were assessed as a minimum every 2 months
from commencement of treatment.
Canakinumab vial sharing and assessment of cost savings
Vial sharing was instituted as part of the clinical CAPS
service at GOSH in November 2015. The paediatric
CAPS clinic occurs monthly, and all patients attend
GOSH for clinical assessment, laboratory investigation
and dosing. One important advantage of centralisation
of care for this very rare disease is that it can facilitate
vial sharing of canakinumab: individual patient doses
(typically, 10 patients per clinic) are made up centrally in
the pharmacy aseptic unit using the required number of
vials to generate these doses resulting in minimum
wastage.
For a full description of how canakinumab is reconsti-
tuted, we refer the reader to the summary of product
characteristics, available at: (https://www.ema.europa.eu/
en/documents/product-information/ilaris-epar-product-
information_en.pdf ). In brief, canakinumab comes in
vials containing 150 mg powder for reconstitution with
1 ml of clear and colourless solvent. After reconstitution,
it has a 24-h refrigerated (4–8 °C) shelf-life. Exact doses
for individual patients are taken from these reconstituted
vials aseptically in pharmacy, for subcutaneous injection
into the patient on the ward on the same day as clinic.
The cost of canakinumab (before and after value
added tax, VAT) was derived from the National Institute
for Health and Care Excellence [Accessed April 21,
2017] (https://www.nice.org.uk/advice/esnm23/chapter/
key-points-from-the-evidence). From that, direct cost
savings were calculated by subtracting the cost of actual
number of vials used from the number of vials that
would have been required if one (or more, if under ex-
ceptional circumstances the canakinumab dose exceeded
150 mg) vials had been allocated to each patient. Phar-
macy costs required to deliver central drug preparation
were also taken into account when calculating the final
cost saving. Using this approach, the actual cost saving
was calculated for a 24 month period starting from
November 1st, 2015 (i.e. spanning 24 clinics). Conserva-
tive projected cost savings based on this were extrapolated
over the next 5 years.
Data handling and statistics
The project utilised descriptive statistics for categorical
data, and summarised as percentage unless otherwise
stated; numeric data were expressed as median and
range. The differences in categorical variables were inves-
tigated using Fisher’s exact test with significance set at a
two-tailed p-value of less than 0.05. Fisher’s exact test was
calculated using a freely available online software (https://
www.graphpad.com/quickcalcs/contingency1.cfm). Micro-
soft Excel 2016 was used to produce a spreadsheet used to




Since its inception in 2011, the paediatric CAPS service
at GOSH has expanded every year, from 14 patients in
2013 to 39 patients who had attended the children’s
CAPS service by the end of 2016. At the time of this
study, the number of patients currently treated by the
service was 28 (11 having been successfully transitioned
to adult care). Of these, 20/28 patients who were receiv-
ing canakinumab were included in this study (Table 1).
The remaining eight patients were excluded due to re-
ceiving anakinra treatment (n = 3) or awaiting treatment
to be commenced (n = 5).
Response to canakinumab
Before commencing canakinumab treatment, the median
CAPS DAS was 6.5/20 (range 0–11/20), with 95% of pa-
tients scoring > 3/20 (Fig. 1). The median SAA before
treatment was 34.8 mg/L (range 0–497; reference range
[RR] less than 10mg/L); and SAA was raised (higher
Table 1 Summary of patients attending the national paediatric
cryopyrin associated periodic fever syndrome service
Total number of patients who ever attended the
GOSH CAPS service
39
Total number of patients included for study 20
Total number of patients with negative
NLRP3 mutation
4
Total number of doses of canakinumab
ever received per patient
Median 14
Range 7–41 doses




CAPS Cryopyrin associated periodic fever syndrome, GOSH Great Ormond
Street Hospital
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than upper RR) in 11/20 (55%) patients (Fig. 2). On
canakinumab, 19/20 (95%) patients had a CAPS DAS ≤ 3
(Fig. 1); and 14/20 (70%) patients had a SAA of < 10mg/
L (Fig. 2). After canakinumab treatment, 15/20 (75%) pa-
tients had CAPS DAS ≤ 3 and a SAA < 10mg/L (Fig. 3).
Safety of canakinumab
Seven patients developed infections after a median treat-
ment period of 16months (range 2–33). These were:
bacterial tracheitis (n = 1); presumed viral upper respiratory
tract infection (n = 1); lower respiratory tract infection, no
organism documented (n = 3); uncomplicated varicella zos-
ter virus infection (n = 1); presumed viral gastroenteritis
(n = 1). Only one infection episode resulted in hospitalisa-
tion for intravenous antibiotics (the case of bacterial trache-
itis, no organism isolated, but prompt response to antibiotic
therapy). There were no other adverse effects documented;
in particular, there were no injection site reactions reported.
Fig. 1 Cryopyrin associated periodic syndrome disease activity score pre-and post canakinumab. The difference between CAPS DAS scores before
and after canakinumab treatment was highly significant (P < 0.0001). A standardised approach was used to monitor CAPS disease activity, as
described previously in this clinic [3]. In brief, this consisted of standardised documentation of clinical disease activity using the CAPS
disease activity score (DAS) (please see Additional file 1). The DAS depicts disease activity using ten symptoms/signs; absence of disease
activity was defined as a score of 0/20; minimal disease activity was depicted by a score ≤ 3/20; and a maximum score of 20 indicated
maximal disease activity. The figure shows that before commencing canakinumab treatment, the median CAPS DAS was 6.5/20 (range 0–11/20),
with 95% of patients scoring > 3/20 (Fig. 1)
Fig. 2 Serum Amyloid A levels score pre-and post canakinumab. Serological response was monitored using serum amyloid A (SAA, reference
range < 10 mg/L). The figure shows that the median SAA before treatment was 34.8 mg/L (range 0–497; reference range [RR] less than 10mg/L);
and SAA was raised (higher than upper RR) in 11/20 (55%) patients (Fig. 2)
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Savings with Canakinumab vial-sharing
Table 2 summarises the actual direct drug cost saving
over a 24-month period starting from November 1st
2015. The total cost of one vial of canakinumab be-
fore value added tax (VAT), as stated by both the
National Institute for Health and Care Excellence
(NICE) and British National Formulary (BNF), is £9927.80
(https://www.nice.org.uk/advice/esnm23/chapter/key-points-
from-the-evidence). The cost for a single vial after VAT is
£11,913.
Vial sharing resulted in an actual direct drug cost sav-
ing of £1,393,821 over a 24-month period. Subtracting
costs associated with central pharmacy canakinumab
preparation (£4000 per annum), the net annual cost
saving was £1,385,821, providing a 5-year projected net
cost saving of approximately £3.5 million (assuming no
further growth in patient numbers).
Discussion
Controlled and uncontrolled studies unequivocally dem-
onstrate that canakinumab is a highly effective and safe
treatment for children and adults with CAPS [3], as re-
inforced by the data presented here. In the context of a
national specially commissioned paediatric CAPS clinical
service, 95% of our paediatric patients achieved minim-
ally active clinical disease activity; and 75% achieved
both minimally active clinical disease and serological re-
mission using a pre-specified definition based on the
CAPS DAS and SAA level. Moreover, canakinumab was
well tolerated, with only one child developing an infec-
tion requiring hospitalisation. Thus, canakinumab is ef-
fective and safe in children with CAPS. Canakinumab,
however, is expensive costing approximately £12,000 per
vial, and many children require less than one vial per
dose. To address this, we designed our clinical service to
facilitate vial sharing having observed considerable drug
wastage in the first 4 years of this specialist clinic.
We first introduced this vial sharing programme in
November 2015, and explored the relative merits but
also potential downsides of such an approach over the
next 24 months. A total of 117 vials were saved over a
24-month period (24 clinics), providing a cost saving of
approximately £1.39 million (which includes VAT, since
in the UK this is added to the cost of medicines adminis-
tered to patients in hospital), after subtracting the
Fig. 3 CAPS disease activity score and Serum Amyloid A levels score pre-and post canakinumab. The difference between CAPS DAS and SAA
scores before and after canakinumab was significant (P < 0.0001). Using these indices, minimally active disease was defined as absent or minimal
disease activity (DAS ≤3/20 with no item scoring as severe) and normal markers of inflammation (SAA < 10mg/L). The CAPS DAS and SAA (plus
other routine investigations: full blood count, renal and liver function; and C-reactive protein) were assessed as a minimum every 2 months from
commencement of treatment. On canakinumab, 19/20 (95%) patients had a CAPS DAS ≤ 3 (Fig. 1); and 14/20 (70%) patients had a SAA of < 10
mg/L (Fig. 2). After canakinumab treatment, 15/20 (75%) patients had CAPS DAS ≤ 3 and a SAA < 10mg/L (Fig. 3)
Table 2 Actual (2015–2017) and 5-year projected cost savings
from canakinumab vial-sharing
Total number of vials used if no vial sharinga 268
Total number of vials used with vial sharinga 151
Total number of vials saved over 24 monthsa 117
Cost of one 150mg canakinumab vial (excluding VAT) £9927.80
Cost of one 150mg canakinumab vial (including VAT) £11,913
Total drug cost without vial sharingb £3,192,684
Total drug cost with vial sharingb £1,798,863
Cost saving from vial sharing over 24 months
(Including preparation cost)
£1,385,821
Projected net cost saving over the next five yearsc
(Including preparation cost)
£3,464,552.50
a1.11.15–31.10.17, spanning 24 clinics; bTotal costs includes VAT, since canakinumab
administered in hospital; cassuming no growth in patient numbers, based on net
cost saving 2015–2017
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modest cost associated with central pharmacy prepar-
ation of individual patient doses. To provide a conserva-
tive estimate of the projected 5-year cost savings, we
assumed that the number of patients treated and num-
ber of vials used would remain constant, which provided
an estimate of a £3.5 m saving over 5 years. Given that
the paediatric CAPS service has thus far grown yearly
since 2011, the actual cost saving may turn out to be
considerably higher. However, we acknowledge that this
is a crude 5-year estimate that could be affected by
changes in patient doses over time that may influence
number of vials saved, and other market forces such as
changes in the price of canakinumab (although we are
not aware of any plans to change the price of canakinu-
mab in the foreseeable future).
This model could have implications for the use of
other high-cost children’s medicines. Our simple
innovation was entirely dependent on running the clinic
on the same day of the month for all CAPS patients,
which enabled us to a priori calculate the total clinic
dose required 2 weeks in advance. Centralised pharmacy
preparation of individual doses used a much reduced
number of canakinumab vials and only required very
modest investment (£4000 per annum). We suggest that
this innovation will help secure resilience for paediatric
CAPS patient access to this high cost medicine for years
to come, whilst generating considerable savings for the
NHS for the foreseeable future. It also improves patient
safety by reducing the likelihood of medication errors
since drug is reconstituted aseptically centrally by a ded-
icated hospital pharmacist. Furthermore, it improves the
patient experience by reducing their length of visit as
doses are prepared ahead of their visits.
General points to consider when contemplating vial-
sharing for other high cost medicines are summarised in
Table 3. Whilst there are clear benefits of centralisation
of highly specialist clinical services, such as (import-
antly) accrual of unique clinical expertise as a direct
consequence of high throughput of patients with an ex-
ceptionally rare disease; and the highlighted economic
benefits we describe here in; two important downsides
are noteworthy. First and foremost, patients have to
travel, sometimes from afar, to the centre of expertise.
This is on the whole manageable for patients with
CAPS, since dosing is every 8 weeks, and additionally
centralises and consolidates clinical expertise for this
ultra-rare disease. Secondly, it is not possible to make
real-time dose changes on the day of the clinic since the
canakinumab is prescribed and prepared in advance. In
practice this is not a major issue for CAPS patients, be-
cause canakinumab has a very long half-life (approxi-
mately 28 days), and therefore dose alterations can safely
occur at the next clinic visit (Table 3). These latter 2
points are however important to consider when contem-
plating vial sharing for other high cost medicines.
Conclusion
In conclusion, canakinumab is highly effective for paedi-
atric patients with CAPS, and demonstrates excellent
safety and tolerability. We demonstrate the cost-
effectiveness of a canakinumab vial-sharing programme,
which inarguably offsets some of the high cost associated
with this treatment. We suggest that this approach
could be applied to other high-cost medicines used in
paediatric practice.
Table 3 Suggested characteristics of a successful vial sharing programme for high cost medicines
Characteristic Comments
Well defined patient population Published diagnostic criteria for CAPS are available, and genetic testing for NLRP3 mutations
is available.
Expensive medicine The cost of one vial of canakinumab is £11,913.
Risk of drug wastage in paediatric population Example: A 10 kg baby with CAPS would have a typical starting dose of 20 mg. This means
that without vial sharing 130mg of the vial would be wasted.
Patients attend single centre on same day as dose This service only applies to NHS England patients; some travel long distances every 8 weeks.
Dosage interval acceptable for regular travel
to single centre
Patients receive canakinumab every 8 weeks, minimising impact on families of regular travel
to the national CAPS clinic.
Sufficient numbers of patients to make vial
sharing feasible
Whilst CAPS as an exceptionally rare disease, centralisation of the national clinic provides
sufficient patient numbers to ensure that vial sharing becomes a feasible and cost-effective
exercise.
Availability of a pharmacy aseptic unit Individual doses need to be made under aseptic conditions to allow vial sharing. Centres will
require an aseptic unit with the capacity to fulfil the demand to implement this innovative
practice.
Nationally commissioned service in place National funding arrangement agreed from NHS England for the use of canakinumab in
patients with CAPS. This was a key aspect facilitating centralisation of care, and thus a viable
vial sharing programme.
Acute “real-time” changes in drug dose not critical Changes in canakinumab dose cannot be made on the day of clinic since this is prescribed
2 weeks in advance. Dosage alteration therefore occurs 8 weeks later at the next clinic visit.
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